Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Asthma
Aerovance announces positive results from phase IIa trial of Aerovant in asthma patients
January 29th, 2007
Aerovance, Inc., announced positive top-line results from a phase IIa trial of inhaled Aerovant in asthma patients. The 30-patient antigen challenge study met its primary endpoint of reducing the severity of late asthmatic response by a statistically significant 72% (p<0.001) compared to baseline following the twice- daily use of inhaled Aerovant (IL-4 and IL-13 antagonist) for 27 days. The study also met the secondary endpoint of decreasing the forced expiratory nitric oxide in patients, indicating a reduction in airway inflammation. Aerovance plans to present the full study results at a scientific conference later this year. "These are very...
Source: Biotech Business Week (2007-01-29)
|
